Logo

Novo Nordisk Signs ActiveSight for Protein Crystallography

Jan 23, 2006

NEW YORK, Jan. 23 (GenomeWeb News) - ActiveSight has signed a deal with Novo Nordisk to provide protein crystallography, the company announced today.

 

Terms of the agreement were not disclosed.

 

ActiveSight is a division of Rigaku that features a portfolio of drug targets for co-crystallography.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.